Cryo-Cell International, Inc. - 10-Q Summary
Business Context and Reporting Period
Company: Cryo-Cell International, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: May 31, 2008
Business Overview: The Company is engaged in cellular processing and cryogenic storage, primarily focusing on umbilical cord blood stem cells (U-Cord®). It also develops new technologies, including the C'elle™ menstrual stem cell preservation program. The Company operates a facility in Oldsmar, Florida, and holds international licensing agreements.
Key Financial Metrics
| Metric | Six Months Ended May 31, 2008 | Six Months Ended May 31, 2007 |
|---|---|---|
| Revenue | $8,685,807 | $8,623,037 |
| Net Loss | $(603,001) | $(2,190,154) |
| Net Loss Per Share (Basic & Diluted) | $(0.05) | $(0.19) |
| Operating Cash Flow | $(173,977) | $(2,333,395) |
| Cash and Cash Equivalents (End of Period) | $3,023,040 | $4,607,731 |
| Total Assets | $10,987,698 | $11,633,709 |
| Total Liabilities | $17,961,805 | $18,224,391 |
| Stockholders' Deficit | $(6,974,107) | $(6,590,682) |
Margin Analysis: Cost of sales represented 35% of revenue for the six months ended May 31, 2008, compared to 36% in the prior year period. The Company reported an operating loss of $(449,138) for the six-month period.
Material Changes vs. Prior Period
- Revenue Stability: Revenue increased slightly by less than 1% year-over-year. This was driven by a 13% increase in recurring annual storage fees, partially offset by a 7% decrease in the number of specimens processed and a 17% decrease in sales discounts.
- Expense Reductions:
- Marketing, General & Administrative (MG&A): Decreased 21% to $5.74 million, primarily due to a 51% drop in legal fees and a 33% reduction in consumer advertising.
- Research & Development (R&D): Decreased 70% to $93,782. The prior year included significant costs for placental stem cell technology which was indefinitely postponed in April 2007. Current R&D focuses on the C'elle™ service.
- Net Loss Improvement: Net loss improved significantly from $(2.19) million to $(0.60) million, largely due to the aforementioned expense reductions.
- Impairment Charges: The Company recorded an impairment charge of $32,940 related to marketable securities deemed to have an other-than-temporary decline in value.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Liquidity: Management anticipates that existing cash, marketable securities, and operating cash flows will be sufficient to fund operations for at least the next 12 months. Capital expenditures are projected at approximately $500,000 for the next year.
- Strategic Focus: The Company is shifting focus from placental stem cells to the commercialization of the C'elle™ menstrual stem cell technology. A new license agreement with LifeCell International Private Ltd. (ACCPL) for India and surrounding regions was signed in March 2008, including a $250,000 upfront fee.
- Revenue Sharing Agreements (RSAs): Interest expense increased to $639,752 (from $543,383) due to payments on RSAs, which are tied to storage revenue in specific geographic areas (NY, TX, FL, IL).
Risks and Contingencies:
- Legal Proceedings:
- PharmaStem Litigation: The Company successfully defended against patent infringement claims in the first round of litigation (patents held invalid). A second round of litigation involving related patents is stayed pending reexamination proceedings, which are expected to conclude favorably.
- Shareholder Derivative Suit: A lawsuit by Mr. David Portnoy regarding the 2007 Annual Meeting was resolved via a special shareholder meeting in March 2008. The Company incurred approximately $292,000 in expenses related to this matter, which were covered by D&O insurance under a court-approved stipulation.
- Warranty Reserves: The Company maintains a reserve of approximately $89,000 for its product warranty and Cryo-Cell Cares™ program. While no claims have been made, a small increase in transplant failure rates could significantly impact this reserve.
- Market Risks: Risks include increased competition, government regulation of stem cell storage, and the market acceptance of new technologies like C'elle™.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $3.02 million cash balance given the negative operating cash flow of $(174k) for the six-month period.
- Revenue Quality: Confirm the trend of recurring storage fees versus one-time processing fees, as the latter declined while the former increased.
- Legal Exposure: Monitor the status of the stayed PharmaStem patent reexamination proceedings and any potential impact on future operations.
- Warranty Liability: Review the assumptions used for the $89,000 warranty reserve, as the Company notes that small changes in failure rates could cause significant adjustments.
- Stock-Based Compensation: Note the $132,000 in stock-based compensation expense and the $207,000 in unrecognized future costs, which will impact future earnings.